Clinical trial commences in healthy adult volunteers to determine appropriate dose of ImmTOR™ to mitigate formation of antibodies to AAV capsids used in gene therapy.
Category: News
AskBio Adds CNS Gene Therapy Programs in Parkinson’s Disease and Multiple System Atrophy
AskBio gains two active clinical programs, proprietary delivery technologies and unique clinical expertise in CNS indications with addition of the Brain Neurotherapy Bio team.
Gene Therapy Leader Katherine High Joins AskBio as President, Therapeutics
Katherine High, MD, has joined the company in the newly formed role of President, Therapeutics and will also serve on its Board of Directors.
AskBio Applauds Commencement of Pfizer’s Pivotal Trial for Duchenne Muscular Dystrophy
Pfizer initiates first pivotal gene therapy trial for DMD based on AskBio’s technology and clinical studies initiated in 2006.
AskBio Welcomes Brain Neurotherapy Bio to Expand Clinical Pipeline for Neurodegenerative Diseases
Led by Dr. Krys Bankiewicz, this team will focus on the clinical translation and development of GDNF gene therapy for Parkinson’s disease and other neurological conditions, such as multiple system atrophy.
AskBio CSO Jude Samulski Named 2020 Business Person of the Year by Triangle Business Journal
The award recognizes executives working in the Triangle area who have consistently driven business success while also demonstrating the power of corporate citizenry.
AskBio and Selecta Receive Orphan Drug Designation for MMA-101 to Treat Methylmalonic Acidemia
The FDA has granted orphan drug and rare pediatric disease designations to AskBio’s gene therapy, MMA-101, for the treatment of methylmalonic acidemia.
Bayer Acquires AskBio to Broaden Innovation Base in Cell and Gene Therapy
AskBio will operate as an independent company on an arm’s-length basis, with a purchase price of $2B upfront and up to $2B in milestone payments.
Selecta and AskBio Receive FDA Rare Pediatric Disease Designation for Methylmalonic Acidemia Gene Therapy
The FDA grants Rare Pediatric Disease Designation to MMA-101 for the treatment of isolated methylmalonic acidemia (MMA) due to methylmalonyl-CoA mutase (MMUT) gene mutations.
Kellie Sears Named AskBio Chief Human Resources Officer
Ms. Sears most recently served as SVP & Interim CHRO at Allergan and will have responsibility for all aspects of AskBio’s human capital management.
